Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer

被引:27
作者
Avigan, D
Wu, Z
Joyce, R
Elias, A
Richardson, P
McDermott, D
Levine, J
Kennedy, L
Giallombardo, N
Hurley, D
Gong, J
Kufe, D
机构
[1] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
stem cell transplantation; breast cancer; cellular and humoral immune reconstitution; dendritic cells;
D O I
10.1038/sj.bmt.1702474
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The present study examines the nature of humoral and cellular immune reconstitution in 28 patients with advanced breast cancer following high-dose chemotherapy with stem cell rescue, patients underwent testing of T, B, NK and dendritic cell function at serial time points until 1 year post transplant or until the time of disease progression. Abnormalities in T cell phenotype and function were observed following high-dose chemotherapy that persisted for at least 6-12 months. The vast majority of patients experienced an inversion of the CD4/CD8 ratio and demonstrated an anergic response to candida antigen. Mean T cell proliferation in response to PHA and to co-culture with allogeneic monocytes was significantly compromised. In contrast, mean Ige and IgA levels were normal 6 months post transplant and NK cell yields and function were transiently elevated following high-dose chemotherapy. Dendritic cells generated from peripheral blood progenitors displayed a characteristic phenotype and were potent inducers of allogeneic T cell proliferation in the post-transplant period. The study demonstrates that patients undergoing autologous transplantation for breast cancer experience a prolonged period of T cell dysfunction, In contrast, B, NK, and DC recover more rapidly. These findings carry significant implications for the design of post-transplant immunotherapy.
引用
收藏
页码:169 / 176
页数:8
相关论文
共 37 条
[1]   A PHASE-II STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN WITH AUTOLOGOUS MARROW SUPPORT IN WOMEN WITH MEASURABLE ADVANCED BREAST-CANCER RESPONDING TO STANDARD-DOSE THERAPY [J].
ANTMAN, K ;
AYASH, L ;
ELIAS, A ;
WHEELER, C ;
HUNT, M ;
EDER, JP ;
TEICHER, BA ;
CRITCHLOW, J ;
BIBBO, J ;
SCHNIPPER, LE ;
FREI, E .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) :102-110
[2]   High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America [J].
Antman, KH ;
Rowlings, PA ;
Vaughan, WP ;
Pelz, CJ ;
Fay, JW ;
Fields, KK ;
Freytes, CO ;
Gale, RP ;
Hillner, BE ;
Holland, HK ;
Kennedy, MJ ;
Klein, JP ;
Lazarus, HM ;
McCarthy, PL ;
Saez, R ;
Spitzer, G ;
Stadtmauer, EA ;
Williams, SF ;
Wolff, S ;
Sobocinski, KA ;
Armitage, JO ;
Horowitz, MM .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :1870-1879
[3]  
ATKINSON K, 1990, BONE MARROW TRANSPL, V5, P209
[4]  
AUCOUTURIER P, 1987, BLOOD, V70, P779
[5]  
BENGTSSON M, 1989, LEUKEMIA, V3, P68
[6]   RECOVERY OF IMMUNOGLOBULIN ISOTYPES FOLLOWING T-CELL DEPLETED ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
BRENNER, MK ;
WIMPERIS, JZ ;
REITTIE, JE ;
PATTERSON, J ;
ASHERSON, GL ;
HOFFBRAND, AV ;
PRENTICE, HG .
BRITISH JOURNAL OF HAEMATOLOGY, 1986, 64 (01) :125-132
[7]   B70/B7-2 IS IDENTICAL TO CD86 AND IS THE MAJOR FUNCTIONAL LIGAND FOR CD28 EXPRESSED ON HUMAN DENDRITIC CELLS [J].
CAUX, C ;
VANBERVLIET, B ;
MASSACRIER, C ;
AZUMA, M ;
OKUMURA, K ;
LANIER, LL ;
BANCHEREAU, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (05) :1841-1847
[8]  
CAYEUX S, 1989, BLOOD, V74, P2270
[9]   Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity [J].
Celluzzi, CM ;
Mayordomo, JI ;
Storkus, WJ ;
Lotze, MT ;
Falo, LD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (01) :283-287
[10]  
FOOT ABM, 1993, BONE MARROW TRANSPL, V11, P7